ATP synthase peripheral stalk-membrane subunit bGenealiases: ATP5F1 · PIG47
Q-omics provides the consensus-scored ATP5PB profile across patient tissues and cancer cell-line models. ATP5PB expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ATP5PB is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, ATP5PB protein abundance shows 28,272 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, LIHC, and GBM as cancer lineages where ATP5PB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5PB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5PB survival associations across molecular data types. ATP5PB RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5PB RNA expression–survival associations across cancer types. High ATP5PB expression shows unfavorable associations in SCLC, ACC, LIHC and LGG, but favorable associations in KIRC and COAD. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ATP5PB RNA expression.
This table summarizes ATP5PB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ATP5PB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5PB shows lower tumor expression in THCA, COAD, KIRC, KICH and HNSC and higher tumor expression in LIHC. The LIHC box plot shows higher ATP5PB RNA expression in tumor versus normal tissue (log2 FC = +0.765, t-test p < 0.001).
This table shows molecular features associated with ATP5PB in patient tissues and cancer cell lines. In patient samples, ATP5PB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP5PB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
